<p>2025 年 9 月 24 日- 上午 9:15</p>
<p><em>新的交易代码 QCLS 将于 2025 年 9 月 25 日星期四生效</em></p>
<p><em>获得许可的技术使公司处于新量子级计算范式的前沿</em></p>
<p>纽约 --（商业资讯）--TNF Pharmaceuticals, Inc.（纳斯达克：TNFA）（“Q/C” 或 “公司”）今天宣布，公司已更名为 Q/C Technologies, Inc.，并将于 2025 年 9 月 25 日星期四市场开盘时在纳斯达克资本市场以新的股票代码 “QCLS” 开始交易。在此之前，公司普通股将继续以当前股票代码 “TNFA” 交易。</p>
<p>新名称 Q/C Technologies 代表了公司最近在量子级计算方面的战略转变，拥有 LightSolver 的光速激光处理单元（LPU）的全球独占权，这是世界上首个基于光和激光的计算系统，应用于加密货币领域。</p>
<p>通过利用光的独特物理特性，LPU 在创新的计算范式中能够将能耗降低高达 90%，同时在速度和效率上超越传统 GPU 甚至量子计算。除了这些性能提升外，LightSolver 的架构旨在提高区块链操作的安全性，为加密货币行业提供更可持续和更具韧性的基础。这些优势预计将使公司处于区块链基础设施创新的前沿。</p>
<p>“我们的新名称和身份更好地反映了公司的未来，” Q/C Technologies 的董事长 Joshua Silverman 表示。“凭借对 LightSolver 创新计算平台在加密领域的独占权，我们正在推进在一个万亿美元行业中的先发策略，该行业面临着盈利和规模化演变的巨大压力。我们相信，这一转型将使我们能够为股东创造显著价值。”</p>
<p>与名称变更和股票代码变更相关，当前股东无需采取任何行动，公司 CUSIP 号码将保持不变。</p>
<p>公司还指出，它继续评估其传统治疗项目 isomyosamine 和 Supera-CBD 的战略选择，旨在在转向下一代计算和区块链基础设施时最大化这些资产的价值。</p>
<p><strong>关于 Q/C Technologies（前身为 TNF Pharmaceuticals）</strong></p>
<p>Q/C Technologies 正在开创下一代节能区块链基础设施。通过与 LightSolver 的许可协议，Q/C 拥有使用创新的量子启发式激光处理单元（LPU）的独占权，这些单元以光速解决计算密集型组合和物理问题。Q/C 在高速光子计算与加密货币基础设施开发之间架起了一座颠覆性的计算范式桥梁，为下一代区块链应用解锁前所未有的性能和可持续性。</p>
<p><strong>关于前瞻性声明的警示声明</strong></p>
<p>本新闻稿可能包含前瞻性声明。这些前瞻性声明涉及已知和未知的风险、不确定性及其他因素，这些因素可能导致实际结果、表现或成就与任何预期的未来结果、表现或成就存在重大差异。前瞻性声明仅在作出之日有效，公司及其附属机构不承担更新前瞻性声明的任何义务。诸如 “预期”、“相信”、“可能”、“估计”、“期望”、“或许”、“计划”、“将”、“会” 等其他类似表达旨在识别这些前瞻性声明，并包括与与 LightSolver 的许可协议预期收益及 LightSolver 技术表现相关的声明。可能导致实际结果与这些前瞻性声明所指示的结果存在重大差异的重要因素包括但不限于：意外的财务挫折，公司需要追求融资选项，这可能因不利的市场条件而对我们的负债产生不利影响，公司维持纳斯达克证券市场上市标准的能力；公司从其制药候选产品中创造价值的能力；公司为其许可技术的商业开发和维持其制药候选产品所需的资金量；竞争加剧；政治、经济或监管条件的变化，以及公司运营的市场中的变化；公司留住和吸引高级管理人员及其他关键员工的能力；公司快速有效应对新技术发展的能力；以及公司保护其商业秘密或其他专有权利的能力，运营时不侵犯他人的专有权利，并防止他人侵犯公司的专有权利。关于公司这些及其他因素的讨论已在公司于 2025 年 4 月 11 日提交的截至 2024 年 12 月 31 日的年度报告 10-K 中列出，以及公司向证券交易委员会提交的后续报告。前瞻性声明仅在作出之日有效，公司不承担修订任何前瞻性声明的意图或义务，无论是由于新信息、未来事件还是其他原因。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTA5MjQ5ODQ5NDhyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTA5MjQ5ODQ5NDhyMQ"/></p>
<p>查看商业资讯上的源版本：https://www.businesswire.com/news/home/20250924984948/en/</p>
<p><strong>投资者联系：</strong></p>
<p>800-507-9010</p>
<p>来源：Q/C Technologies, Inc.</p>

TNFA

QCLS

<p>TNF Pharmaceuticals 已更名为 Q/C Technologies，并将于 2025 年 9 月 25 日开始以新股票代码 "QCLS" 交易。这一品牌重塑反映了公司在量子级计算方面的战略重点，特别是在加密货币领域，利用对 LightSolver 激光处理技术的独家权利。这项新技术承诺为区块链操作提供显著的节能和增强的安全性。当前股东无需对名称和代码的变更采取任何行动，公司仍在探索其传统治疗项目的选项</p>

<p>09/24/2025 - 09:15 AM</p>
<div class="lb-trans"><p>2025 年 9 月 24 日- 上午 9:15</p>
</div><p><em>New trading symbol QCLS effective Thursday, September 25, 2025</em></p>
<div class="lb-trans"><p><em>新的交易代码 QCLS 将于 2025 年 9 月 25 日星期四生效</em></p>
</div><p><em>Licensed technology positions Company at forefront of new quantum-class computing paradigm</em></p>
<div class="lb-trans"><p><em>获得许可的技术使公司处于新量子级计算范式的前沿</em></p>
</div><p>NEW YORK--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“Q/C” or the “Company”) today announced that it has changed its corporate name to Q/C Technologies, Inc. and will begin trading under the new ticker symbol “QCLS” on the Nasdaq Capital Market, effective as of the market open on Thursday, September 25, 2025. Until then, the Company’s common stock will continue to trade under its current ticker symbol “TNFA.”</p>
<div class="lb-trans"><p>纽约 --（商业资讯）--TNF Pharmaceuticals, Inc.（纳斯达克：TNFA）（“Q/C” 或 “公司”）今天宣布，公司已更名为 Q/C Technologies, Inc.，并将于 2025 年 9 月 25 日星期四市场开盘时在纳斯达克资本市场以新的股票代码 “QCLS” 开始交易。在此之前，公司普通股将继续以当前股票代码 “TNFA” 交易。</p>
</div><p>The new name Q/C Technologies represents the Company’s recent strategic pivot into quantum-class computing with exclusive global rights to LightSolver’s light-speed laser processing unit (LPU), the world’s first light and laser-based computing system, for application in the cryptocurrency vertical.</p>
<div class="lb-trans"><p>新名称 Q/C Technologies 代表了公司最近在量子级计算方面的战略转变，拥有 LightSolver 的光速激光处理单元（LPU）的全球独占权，这是世界上首个基于光和激光的计算系统，应用于加密货币领域。</p>
</div><p>By harnessing the unique physical properties of light in an innovative computing paradigm, the LPUs can reduce energy consumption by up to 90% while outperforming traditional GPUs and even quantum computing in both speed and efficiency. In addition to these performance gains, Lightsolver’s architecture is designed to improve security for blockchain operations, offering a more sustainable and resilient foundation for the cryptocurrency industry. Together, these advantages are expected to position the Company to be at the forefront of innovation in blockchain infrastructure.</p>
<div class="lb-trans"><p>通过利用光的独特物理特性，LPU 在创新的计算范式中能够将能耗降低高达 90%，同时在速度和效率上超越传统 GPU 甚至量子计算。除了这些性能提升外，LightSolver 的架构旨在提高区块链操作的安全性，为加密货币行业提供更可持续和更具韧性的基础。这些优势预计将使公司处于区块链基础设施创新的前沿。</p>
</div><p>“Our new name and identity better reflect the Company’s future,” said Joshua Silverman, Chairman of Q/C Technologies. “With exclusive rights to LightSolver’s innovative computing platform for the crypto vertical, we are advancing a first-mover strategy in a trillion-dollar industry under immense pressure to evolve profitably and at scale. We believe that this transformation will position us to create significant value for our shareholders.”</p>
<div class="lb-trans"><p>“我们的新名称和身份更好地反映了公司的未来，” Q/C Technologies 的董事长 Joshua Silverman 表示。“凭借对 LightSolver 创新计算平台在加密领域的独占权，我们正在推进在一个万亿美元行业中的先发策略，该行业面临着盈利和规模化演变的巨大压力。我们相信，这一转型将使我们能够为股东创造显著价值。”</p>
</div><p>In connection with the name change and stock symbol change, no action is required from current shareholders and the Company’s CUSIP number will remain the same.</p>
<div class="lb-trans"><p>与名称变更和股票代码变更相关，当前股东无需采取任何行动，公司 CUSIP 号码将保持不变。</p>
</div><p>The Company also noted that it continues to evaluate strategic options for its legacy therapeutic programs, isomyosamine and Supera-CBD, with the goal of maximizing value from these assets as it pivots into next-generation computing and blockchain infrastructure.</p>
<div class="lb-trans"><p>公司还指出，它继续评估其传统治疗项目 isomyosamine 和 Supera-CBD 的战略选择，旨在在转向下一代计算和区块链基础设施时最大化这些资产的价值。</p>
</div><p><strong>About Q/C Technologies (formerly TNF Pharmaceuticals)</strong></p>
<div class="lb-trans"><p><strong>关于 Q/C Technologies（前身为 TNF Pharmaceuticals）</strong></p>
</div><p>Q/C Technologies is pioneering the next generation of energy-efficient blockchain infrastructure.Through a licensing agreement with LightSolver, Q/C holds exclusive rights to the use of innovative quantum-inspired laser-based processing units (LPUs) that solve compute-intensive combinatorial and physical problems at the speed of light. Q/C bridges a disruptive computing paradigm for high-speed photonic computing with cryptocurrency infrastructure development at scale, unlocking unprecedented performance and sustainability for next generation blockchain applications.</p>
<div class="lb-trans"><p>Q/C Technologies 正在开创下一代节能区块链基础设施。通过与 LightSolver 的许可协议，Q/C 拥有使用创新的量子启发式激光处理单元（LPU）的独占权，这些单元以光速解决计算密集型组合和物理问题。Q/C 在高速光子计算与加密货币基础设施开发之间架起了一座颠覆性的计算范式桥梁，为下一代区块链应用解锁前所未有的性能和可持续性。</p>
</div><p><strong>Cautionary Statement Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示声明</strong></p>
</div><p>This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “plan,” “will,” “would’’ and other similar expressions are intended to identify these forward-looking statements and include statements related to the expected benefits from the licensing agreement with LightSolver and performance of LightSolver’s technology. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: unanticipated financial setbacks, the Company needing to pursue financing options that could adversely impact our liabilities due to adverse market conditions, the Company’s ability to maintain compliance with the Nasdaq Stock Market’s listing standards; the Company’s ability to create value from its pharmaceutical candidates; the amount of funds the Company requires for the commercial development of its licensed technology and maintenance of its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company’s ability to retain and attract senior management and other key employees; the Company’s ability to quickly and effectively respond to new technological developments; and the Company’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company’s proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.</p>
<div class="lb-trans"><p>本新闻稿可能包含前瞻性声明。这些前瞻性声明涉及已知和未知的风险、不确定性及其他因素，这些因素可能导致实际结果、表现或成就与任何预期的未来结果、表现或成就存在重大差异。前瞻性声明仅在作出之日有效，公司及其附属机构不承担更新前瞻性声明的任何义务。诸如 “预期”、“相信”、“可能”、“估计”、“期望”、“或许”、“计划”、“将”、“会” 等其他类似表达旨在识别这些前瞻性声明，并包括与与 LightSolver 的许可协议预期收益及 LightSolver 技术表现相关的声明。可能导致实际结果与这些前瞻性声明所指示的结果存在重大差异的重要因素包括但不限于：意外的财务挫折，公司需要追求融资选项，这可能因不利的市场条件而对我们的负债产生不利影响，公司维持纳斯达克证券市场上市标准的能力；公司从其制药候选产品中创造价值的能力；公司为其许可技术的商业开发和维持其制药候选产品所需的资金量；竞争加剧；政治、经济或监管条件的变化，以及公司运营的市场中的变化；公司留住和吸引高级管理人员及其他关键员工的能力；公司快速有效应对新技术发展的能力；以及公司保护其商业秘密或其他专有权利的能力，运营时不侵犯他人的专有权利，并防止他人侵犯公司的专有权利。关于公司这些及其他因素的讨论已在公司于 2025 年 4 月 11 日提交的截至 2024 年 12 月 31 日的年度报告 10-K 中列出，以及公司向证券交易委员会提交的后续报告。前瞻性声明仅在作出之日有效，公司不承担修订任何前瞻性声明的意图或义务，无论是由于新信息、未来事件还是其他原因。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTA5MjQ5ODQ5NDhyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250924984948r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20250924984948/en/</p>
<div class="lb-trans"><p>查看商业资讯上的源版本：https://www.businesswire.com/news/home/20250924984948/en/</p>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p>800-507-9010</p>
<div class="lb-trans"><p>800-507-9010</p>
</div><p>Source: Q/C Technologies, Inc.</p>
<div class="lb-trans"><p>来源：Q/C Technologies, Inc.</p>
</div>

TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol “QCLS” to Reflect Strategic Focus on Quantum Class Photonic Computing | TNFA Stock News

TNF Pharmaceuticals 宣布更名为 Q/C Technologies，并将股票代码更改为 “QCLS”，以反映其在量子级光子计算领域的战略重点 | TNFA 股票新闻